Recessive	O
mutations	O
in	O
a	O
distal	B-ENHANCER
PTF1A	I-ENHANCER
enhancer	E-ENHANCER
cause	O
isolated	O
pancreatic	O
agenesis	O
.	O


The	O
contribution	O
of	O
cis	O
-	O
regulatory	O
mutations	O
to	O
human	O
disease	O
remains	O
poorly	O
understood	O
.	O


Whole	O
-	O
genome	O
sequencing	O
can	O
identify	O
all	O
noncoding	O
variants	O
,	O
yet	O
the	O
discrimination	O
of	O
causal	O
regulatory	O
mutations	O
represents	O
a	O
formidable	O
challenge	O
.	O


We	O
used	O
epigenomic	O
annotation	O
in	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
-	O
derived	O
pancreatic	O
progenitor	O
cells	O
to	O
guide	O
the	O
interpretation	O
of	O
whole	O
-	O
genome	O
sequences	O
from	O
individuals	O
with	O
isolated	O
pancreatic	O
agenesis	O
.	O


This	O
analysis	O
uncovered	O
six	O
different	O
recessive	O
mutations	O
in	O
a	O
previously	O
uncharacterized	O
~	B-ENHANCER
400	I-ENHANCER
-	I-ENHANCER
bp	I-ENHANCER
sequence	I-ENHANCER
located	I-ENHANCER
25	I-ENHANCER
kb	I-ENHANCER
downstream	I-ENHANCER
of	I-ENHANCER
PTF1A	E-ENHANCER
(	O
encoding	O
pancreas	O
-	O
specific	O
transcription	O
factor	O
1a	O
)	O
in	O
ten	O
families	O
with	O
pancreatic	O
agenesis	O
.	O


We	O
show	O
that	O
this	O
region	O
acts	O
as	O
a	O
developmental	B-ENHANCER
enhancer	I-ENHANCER
of	I-ENHANCER
PTF1A	E-ENHANCER
and	O
that	O
the	O
mutations	O
abolish	O
enhancer	O
activity	O
.	O


These	O
mutations	O
are	O
the	O
most	O
common	O
cause	O
of	O
isolated	O
pancreatic	O
agenesis	O
.	O


Integrating	O
genome	O
sequencing	O
and	O
epigenomic	O
annotation	O
in	O
a	O
disease	O
-	O
relevant	O
cell	O
type	O
can	O
thus	O
uncover	O
new	O
noncoding	O
elements	O
underlying	O
human	O
development	O
and	O
disease	O
.	O
